Therapeutic advances in the management of metastatic colorectal cancer

References

• Parkin DM, Muir CS, Whelan SL, Ghao YT, Ferlay J, Powell J. Cancer incidence in five continents. IARC scientific publications, Lyon, France, 120 (1992).
   Google Scholar
• Sant M, Capocaccia R, Verdecchia A et al. The Eurocare working group. Comparisons of colon-cancer survival among european countries: the Eurocare study. Int. j Cancer 63, 43–48 (1995).
   Google Scholar
• Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care versus supportive care alone in patients with metastatic colorectal cancer. BE Med 306, 752–755 (1993).
   Google Scholar
• Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer, a randomized trial. j Clin. 0=1 10, 904–911 (1992).
   Google Scholar
• •This is the first paper demonstrating the usefulness of chemotherapy in asymptomatic patients having metastases from colorectal cancer. To be eligible, patients should have no disease-related symptom. They were randomized between 5-FU-based chemotherapy and no treatment; the patients who received no initial treatment were given chemotherapy at occurrence of disease-related symptoms. The results clearly indicated that patients who received initial chemotherapy were more likely to stay symptom-free at 6 and 12 months. There was also a survival benefit in this group of patients.
   Google Scholar
• Rougier P, Buyse M, Ryan R et al. Meta- analysis of all trials comparing intravenous bolus administration to continuous infusion of 5-fluorouracil in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. 0=1 16, 267a (1997) (Abstract).
   Google Scholar
• Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. j Clin. Oncol 10, 896–903 (1992).
   PubMedGoogle Scholar
• Jager E, Heike M, Bernhardt H et al. Weekly high-dose leucovorin versus low- dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. j Clin. Oncol 14, 2274–2279 (1996).
   PubMedGoogle Scholar
• Scheithauer W, Kornek G, Marczell A et al. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure L-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized Phase III study. j Clin. Oncol 15, 908–914 (1997).
   PubMedGoogle Scholar
• Advanced Colorectal Cancer Meta-analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. j Clin. 0=1 12, 960–969 (1994).
   Google Scholar
• Blijham G, Wagener T, Wils J et al. Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. Clin. Oncol 14, 2266–2273 (1996).
   Google Scholar
• Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon oc2a or leucovorin for advanced colorectal cancer. Clin. Oncol 13, 921–928 (1995).
   Google Scholar
• Kosmidis PA, Tsavaris N, Skarlos D et al Fluorouracil and leucovorin with or without interferon oc2b in advanced colorectal cancer: analysis of a prospective randomized Phase III trial. Hellenic Cooperative Oncology Group. j Clin. Oncol 14, 2682–2687 (1996).
   Google Scholar
• Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmation of evidence of improved therapeutic efficacy in advanced colorectal cancer. j Clin. 0=1 9, 1967–1972 (1991).
   Google Scholar
• Petrelli N, Douglass HO, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized Phase III trial. Gastrointestinal Tumor Study Group. j Clin. 0=1 7, 1419–1426 (1989).
   Google Scholar
• De Gramont A, Bosset JF, Milan C etal. Randomized trial comparing low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion in metastatic colorectal cancer: a French Intergroup Study. j Clin. 0=1 15, 808–815 (1997).
   Google Scholar
• •The interest of this study is to demonstrate the validity of the association of 5-FU bolus + continuous infusion in a bi-monthly regimen. A significant gain was obtained in probability of response and in progression-free survival and the patients' quality of life was also improved.
   Google Scholar
• Kohne CH, Schoffski P, Wilke H et al. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. j Clin. Oncol 16, 418–426 (1998).
   Google Scholar
• Gamelin E, Dorval E, Dumesnil Y et al. Relationship between 5-fluorouracil dose-intensity and therapeutic response in patients with advanced colorectal cancer receiving 5-FU-containing infusional therapy. Cancer 77, 441–451 (1996).
   PubMed Web of Science ®Google Scholar
• Gamelin E, Jacob J, Danquechin-Dorval E et al. Multicentre randomized trial comparing in weekly treatment of advanced colorectal cancer intensified 5-fluorouracil and folinic acid with 5-FU pharmacokinetic monitoring to a constant dose calculated with body-surface area. Proc. Am. Soc. Clin. Oncol, Los Angeles, USA, 17, 270a, 1039 (1998).
   Google Scholar
• Raymond E, Buquet-Fagot C, Djelloul S et al Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidilate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 8, 876–885 (1997).
   PubMed Web of Science ®Google Scholar
• Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive Phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol 7, 95–98 (1996).
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Sastre J, Zaniboni A et al. Oxaliplatin as single-agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. 0=1 9, 105–108 (1998).
   Google Scholar
• Becouarn Y, Ychou M, Ducreux M et al A Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. j Clin. Oncol 8, 2739–2744 (1998).
   Google Scholar
• Maindrault-Goebel F, Louvet C, Carola E et al. Oxaliplatin reintroduction in patients pretreated with leucovorin, 5-FU and oxaliplatin for metastatic colorectal cancer. A GERCOR study. Proc. Am. Soc. Gun. Oncol, New Orleans, USA, 19, 255a, 990 (2000).
   Google Scholar
• De Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. Cancer 33, 214–219 (1997).
   Google Scholar
• André T, Louvet C, Raymond E et al. Bimonthly high-dose leucovorin, 5-fluorouracil 48-hour infusion and oxaliplatin (FOLFOX 3) for metastatic colorectal cancer resistant to the same LV5FU2 regimen. Ann. Oncol 9, 1251–1253 (1998).
   Google Scholar
• Levi F, Zidani R, Vannetzel JM et al. Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multi-institutional trial. j Natl Cancer Inst. 86, 1608–1617 (1994).
   Google Scholar
• Giacchetti S, Perpoint B, Zidani N et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Oncol 18, 136–147 (2000). This study is largely described inside the present article.
   Google Scholar
• De Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. j Gun. Oncol 18, 2938–2947 (2000). This study is largely described inside the present article.
   Google Scholar
• Cunningham D, Pyrhönen S, James RD et a/. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352, 1413–1418 (1998).
   Google Scholar
• ••In this article, the authors showed that asurvival gain could be obtained even with second-line treatments in metastatic colorectal cancer patients, whereas several decades had been necessary to assess the usefulness of first-line treatments. This revolution was due to the development of new drugs, such as irinotecan.
   Google Scholar
• Rougier P, Van Cutsem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352, 1407–1412 (1998).
   PubMed Web of Science ®Google Scholar
• ••In this article, the authors showed that asurvival gain could be obtained even with second-line treatments in metastatic colorectal cancer patients, whereas several decades had been necessary to assess the usefulness of first-line treatments. This revolution was due to the development of new drugs, such as irinotecan.
   Google Scholar
• Boige V, Raymond E, Armand JR Irinotecan: drug schedule, research of combinations and Phase I experiences. Bull. Cancer Special Issue, 26–32 (1998).
   Google Scholar
• Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. j Gun. Oncol 15, 251–260 (1997).
   Web of Science ®Google Scholar
• Pitot HC, Wender DB, O'Connell MJ et al Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Oncol 15, 2910–2919 (1997).
   Google Scholar
• Allen M, Cunningham D, Schmitt C. The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma : recent quality of life studies. Anticancer Drugs 9, 783–790 (1998).
   PubMedGoogle Scholar
• Freyer G, Rougier P, Bugat R et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5-FU failure. BE Cancer83, 431–437 (2000).
   Google Scholar
• Vanhoefer U, Harstrick A, Köhne CH et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. j Gun. Oncol 17, 907–913 (1999).
   Google Scholar
• Ducreux M, Ychou M, Seitz JF et al Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil and high-dose leucovorin every two weeks (LV5-FU2 regimen): a dose- finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. j Gun. Oncol 17, 2901–2908 (1999).
   Google Scholar
• Salz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl. Merl 343, 905–914 (2000). This study demonstrated that the use of a new drug — namely irinotecan — in association with 5-FU as first-line treatment was clearly superior to the use of 5-FU alone. In our opinion, this is one of the studies showing that a new drug should be given in association with 5-FU to all patients, except in case of contraindication.
   Google Scholar
• Douillard JY, Cunningham D, Roth AD et a/. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041–1047 (2000). This study demonstrated that the use of a new drug — namely irinotecan — in association with 5-FU as first-line treatment was clearly superior to the use of 5-FU alone. In our opinion, this is one of the studies showing that a new drug should be given in association with 5-FU to all patients, except in case of contraindication.
   Google Scholar
• Zalcberg JR, Cunningham D, Van Cutsem E et al. ZD 1694: a novel thymidilate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. j Clin. Oncol 14, 716–721 (1996).
   Google Scholar
• Cunningham D, Zalcberg JR, Ruth U et al. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol 7, 961–965 (1996).
   Google Scholar
• Pazdur R, Vincent M. Raltitrexed versus 5- fluorouracil and leucovorin in patients with advanced colorectal cancer: results of a randomised, multicenter, North American trial. Proc. Am. Soc. Clin. Oncol, Denver, USA, 16, 228a, 801 (1997).
   Google Scholar
• Harper P Advanced colorectal cancer: results from the latest raltitrexed comparative study. Pmc. Am. Soc. Clin. Oncol, Denver, USA, 16, 228a, 802 (1997).
   Google Scholar
• Douillard JY, Michel P, Gamelin E et al Raltitrexed plus oxaliplatin: an active combination for first-line chemotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Gun. °nevi, New Orleans, USA, 19, 250a, 971 (2000).
   Google Scholar
• Pazdur R, Douillard JY, Skillings JR et al Multicenter Phase III study of 5-fluorouracil or UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc. Am. Soc. Gun. Oncol, Atlanta, USA, 18, 263a, 1009 (1999).
   Google Scholar
• Carmichael J, Popiela T, Radstone D et al. Randomized comparative study of Orzel (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus' parenteral 5-fluorouracil plus LV in patients with metastatic colorectal cancer. Proc. Am. Soc. Gun. awl, Atlanta, USA, 18, 262a, 1015 (1999).
   Google Scholar
• Twelves C, Harper P, Van Cutsem E et al. A Phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc. Am. Soc. Gun. Oncol Atlanta, USA, 19, 263a, 1010 (1999).
   Google Scholar
• Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. j Natl Cancer Inst. 88, 252–258 (1996).
   PubMedGoogle Scholar
• Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. j Gun. Oncol 18, 243–254 (2000).
   Google Scholar
• Kemeny N, Huang Y, Cohen A et al Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl. j Merl 341, 2039–2048 (1999).
   PubMed Web of Science ®Google Scholar
• Scheel J, Strangl R, Altendorf-Hoffman A, Paul M. Resection of colorectal liver metastases. World 1. Sorg. 19, 59–71 (1995).
   Google Scholar
• Suzuki S, Nakamura S, Ochiai H et al. Surgical management of recurrence after resection of colorectal liver metastases. J. Hep. Bit. Pancr Sorg. 4, 103–112 (1997).
   Google Scholar
• Jaeck D, Bachellier P, Guiguet M et al. Long-term survival following resection of colorectal hepatic metastases. BE J. Sorg. 84, 977–980 (1997).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Guiguet M, Valliant JC et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77, 1254–1262 (1996).
   Google Scholar
• Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Sorg. 224, 509–522 (1996).
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Itzhaki M, Gruia G et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. awl 10, 663–669 (1999).
   Google Scholar